This is a U.S. news story, published by Yahoo, that relates primarily to Ebglyss news.
For more U.S. news, you can click here:
more U.S. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
eczema drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest severe eczema news, eczema news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
National Eczema AssociationReuters
•81% Informative
Ebglyss is a monoclonal antibody that selectively targets and neutralizes the IL-13 protein that causes progression of eczema.
The FDA 's approval was based on three studies involving over 1,000 patients.
Nearly 16.5 million adults in the U.S. have Eczema , also known as atopic dermatitis, which can cause itching, rashes and dry patches.
VR Score
91
Informative language
97
Neutral language
78
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links